Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience.
Carmen CantisaniNorbert KissAhmad Faiq NaqeshbandiGiulio TostiSonia TofaniClaudio CartoniIda CarmosinoFranca CantoresiPublished in: Dermatologic therapy (2019)
Nonmelanoma skin cancer is the most common malignant tumor in the fair skin population, with each year several millions of diagnosed cases. Their most common risk factors are fair skin, a history of excessive ultraviolet light exposure, chronic inflammatory skin conditions, exposure to radiation, and contact with arsenic. Certain drugs can also be associated with a higher risk of nonmelanoma skin cancer. These include hydroxyurea, which acts as a metabolic inhibitor of ribonucleotide reductase and a potent nonalkylating myelosuppressive agent. It is used for the treatment of various myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia. Several publications describe an increased occurrence of skin manifestations following hydroxyurea treatment. A growing body of evidence indicates a possible role of hydroxyurea in skin cancer progression. In this review article, we summarize some relevant observations about the association of hydroxyurea and skin cancer, and we describe our own clinical experiences to provide up to date recommendations about the care of patients on hydroxyurea therapy.
Keyphrases
- skin cancer
- sickle cell disease
- risk factors
- soft tissue
- healthcare
- end stage renal disease
- systematic review
- chronic kidney disease
- heavy metals
- palliative care
- oxidative stress
- ejection fraction
- physical activity
- chronic myeloid leukemia
- body mass index
- replacement therapy
- bone marrow
- quality improvement
- clinical practice
- combination therapy
- chronic pain
- patient reported
- cell therapy
- weight gain
- smoking cessation
- patient reported outcomes
- anti inflammatory
- health insurance